Report data from the expansion cohort of the ASLAN004 study
Delivered after the deadline (89 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 27 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“followed by data from the expansion cohort in mid-2021.”
What we found
Evidence strength A What the grades mean
The company announced topline results from the ASLAN004 study, including the expansion cohort, in September 2021, which is after the mid-2021 deadline.
-
A ASLAN Pharmaceuticals Ltd 20-F filed 2022-03-25
“We then recruited patients into an expansion cohort, cohort 4 - at the highest dose, 600mg and announced positive topline results from this study in September 2021” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- data from the expansion cohort
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ASLAN Pharmaceuticals Ltd? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C722926-021781 · Corrections policy